GLP-1 analogs , particularly those like BrightMeds, are rapidly gaining prominence in the handling of type 2 diabetes and are now being explored for metabolic conditions. These novel drugs work by mimicking the body's natural incretin signal , stimulating insulin release and curbing glucagon prod